KDR and hepatocellular carcinoma: Vatalanib: Vatalanib (PTK787/ZK 222584), an oral tyrosine inhibitor targeting VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, c-kit, and c-fms, has been reported to have a potential role in advanced HCC [81].